REDWOOD CITY, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The presentation was made at the Chemotherapy Foundation Symposium taking place in New York City from November 10 to 14, 2009.
The presentation, Targeting Tumor Hypoxia with TH-302: Phase I Results with Monotherapy and in Combination with Chemotherapy, was given by Dr. Sant P. Chawla, M.D., Director of the Sarcoma Oncology Center in Santa Monica, California, and a clinical investigator for the trial.
The presentation summarized the interim clinical trial results from three ongoing clinical trials being conducted with TH-302. Over the last several months, interim data from each of these studies has been presented at various oncology conferences focused on the treatment of lung cancer, melanoma, soft tissue sarcoma, and solid tumors in general. Dr. Chawla's presentation provided an overview of these data which are discussed in previous Company news releases.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit the website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding TH-302's uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on November 5, 2009 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." Threshold does not intend to update any forward-looking statement made in this news release.